Trading Signals: ABBV Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Fri. Dec. 22, 2023)(AbbVie Inc.)
| ABBV latest price $60.2005 (-0.87%) ($60.1449 - $60.9470) on Mon. Apr. 10, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 0.83% (three month average) | RSI | 45 | Latest Price | $60.2005(-0.87%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | ABBV declines -0.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ABBV advance at 0% a week (0% probability) XLV(61%) VYM(49%) IVE(47%) IWD(47%) SPLV(47%) | Factors Impacting ABBV price | ABBV will decline at least -0.415% in a week (0% probabilities). VIXM(-17%) TLT(-13%) UUP(-10%) IGOV(-4%) IPO(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.415% (StdDev 0.83%) | Hourly BBV | 0 () | Intraday Trend | -0.8% | | | |
|
Resistance Level | $60.72 | 5 Day Moving Average | $60.35(-0.25%) | 10 Day Moving Average | $60.5(-0.5%) | 20 Day Moving Average | $60.72(-0.86%) | To recent high | -2.4% | To recent low | 8.3% | Market Cap | $106.211b | | | | AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |